Early Antiviral Responses to Rhinovirus Infection in Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-11

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The bulk of the morbidity and mortality related to asthma is during periods of acutely increased symptomatology called 'exacerbations'. Roughly half of asthma sufferers experience such an exacerbation each year. Most of these events are triggered by viral infections, usually the common cold virus (rhinovirus).

A key part of the body's defence against viral infections is to produce antiviral proteins called 'interferons', which have a myriad of effects to stop viruses. Previous work on cells taken from volunteers with asthma and healthy controls and infected with rhinovirus in the lab suggests interferon production is impaired in asthma. However when human volunteers with asthma are infected with rhinovirus, high levels of interferon are found a few days later - along with high numbers of virus. Whether the high virus numbers are the result of an initially weak interferon response, with subsequently unchecked viral replication leading to exaggerated interferon levels, is unknown as no one has measured interferons early in infection.

By infecting volunteers with asthma and healthy controls with rhinovirus at a known time, only done in a handful of centres worldwide, we will be able to measure interferons within hours of infection and well before symptoms develop.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms of Rhinovirus Induced Asthma Exacerbations

NCT01159782

Rhinovirus Infection in Asthma

COMPLETED NA

Mechanisms of Interplay Between Allergy and Viruses in Asthma

NCT01773590

Rhinovirus Infection in Asthma

COMPLETED NA

Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic

NCT02111772

Asthma

COMPLETED NA

Airway Remodeling and Rhinovirus in Asthmatics

NCT05775952

Asthma Respiratory Disease

RECRUITING

Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations

NCT01520051

Asthma Viral Infection

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asthma

Rhinovirus infection

Intervention Type OTHER

Inoculation with rhinovirus-16

Healthy controls

Rhinovirus infection

Intervention Type OTHER

Inoculation with rhinovirus-16

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rhinovirus infection

Inoculation with rhinovirus-16

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-55 years
* Doctor diagnosis of asthma
* Previous asthma exacerbation

• Age 18-55 years

Exclusion Criteria

* Smoking history over past 12 months
* Sinonasal disease, including current symptoms of allergic rhinitis
* Asthma exacerbation or an upper respiratory viral infection within the previous six weeks
* Current or concomitant use of oral steroids, monoclonal antibodies or nasal sprays
* Neutralising antibodies to rhinovirus (RV)-16
* Clinically significant diseases other than asthma which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, influence the results of the study, an/or the patient's ability to take part in it
* Inability to understand written or verbal information in English

For healthy control group:

As for Asthma group and in addition:

• History of asthma

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes